Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
about
Biosimilars: Key regulatory considerations and similarity assessment tools.Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory GuidelinesPatients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey
P2860
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
@ast
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
@en
type
label
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
@ast
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
@en
prefLabel
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
@ast
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
@en
P2093
P2860
P921
P356
P1476
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
@en
P2093
Fritz Sörgel
Markus Zabransky
Martin Schiestl
P2860
P304
P356
10.2147/DDDT.S130318
P407
P577
2017-05-16T00:00:00Z